Stockscreener 앱 받기
37.80
0.59%
0.22
시간 외 거래:
37.91
0.11
+0.29%
전일 마감가:
$37.58
열려 있는:
$37.71
하루 거래량:
3.41M
Relative Volume:
0.66
시가총액:
$77.12B
수익:
$40.95B
순이익/손실:
$4.43B
주가수익비율:
17.61
EPS:
2.1468
순현금흐름:
$6.10B
1주 성능:
+0.64%
1개월 성능:
-1.77%
6개월 성능:
+4.88%
1년 성능:
-5.55%
1일 변동 폭
$37.67
$37.97
1주일 범위
$36.75
$37.97
52주 변동 폭
$31.71
$44.67
글락소스미스클라인 ADR Stock (GSK) Company Profile
GSK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
37.80 | 74.13B | 40.95B | 4.43B | 6.10B | 2.1468 |
|
LLY
Lilly Eli Co
|
625.65 | 670.04B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
173.33 | 410.84B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.05 | 346.78B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
116.84 | 219.72B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.69 | 198.42B | 63.62B | 16.41B | 14.72B | 6.49 |
글락소스미스클라인 ADR Stock (GSK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-03 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-04-15 | 개시 | Exane BNP Paribas | Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-11-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-07-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-03-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2024-01-03 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-03-17 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-02-27 | 재개 | Goldman | Buy |
| 2023-01-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-11 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-09-15 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-21 | 재개 | Citigroup | Neutral |
| 2022-02-11 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2021-06-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2021-03-23 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | 개시 | Deutsche Bank | Hold |
| 2020-11-02 | 업그레이드 | Liberum | Hold → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-02-12 | 다운그레이드 | Shore Capital | Hold → Sell |
| 2020-01-16 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2019-12-02 | 개시 | SVB Leerink | Outperform |
| 2019-11-21 | 업그레이드 | UBS | Neutral → Buy |
| 2019-10-11 | 업그레이드 | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | 재개 | Citigroup | Neutral |
| 2019-09-03 | 업그레이드 | Societe Generale | Sell → Buy |
| 2019-08-13 | 재개 | JP Morgan | Neutral |
| 2019-06-17 | 재개 | Morgan Stanley | Underweight |
| 2019-03-08 | 다운그레이드 | Shore Capital | Buy → Hold |
| 2019-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-01-14 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-08-30 | 다운그레이드 | Liberum | Buy → Hold |
| 2018-04-04 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | 업그레이드 | Kepler | Reduce → Hold |
모두보기
글락소스미스클라인 ADR 주식(GSK)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK - GlobeNewswire Inc.
The Best Healthcare Stocks to Buy - Morningstar
What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar
Company News for Jul 31, 2025 - The Globe and Mail
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise - TradingView
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
GSK Plc ADR (GSK) Stock: A Year of Stock Market Dynamics - investchronicle.com
Fifth Third Bancorp Inc. (FITB) Price Performance Over the Years: A Comparative Study - investchronicle.com
Navigating YMM Stock: Full Truck Alliance Co Ltd ADR Journey - investchronicle.com
GDS Holdings Limited ADR (GDS) Stock: Navigating a Year of Volatility - investchronicle.com
The Future of Microvast Holdings Inc: Analyzing MVST - investchronicle.com
SES AI Corporation (SES) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
SKYQ’s Stock Woes: Down -53.24% in 6 Months, Down -53.24% in Just 5 Days - investchronicle.com
Antero Resources Corp (AR) Stock: A Year of Declines and Increases - investchronicle.com
The Psychology of HUYA Inc ADR Inc. (HUYA) Price Performance: Understanding Market Sentiment - investchronicle.com
American Resources Corporation: Analyzing AREC Stock Trends - investchronicle.com
MSP Recovery Inc (MSPR) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Coty Inc (COTY) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Behind Palladyne AI Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
NVO’s 2025 Market Dance: Down -51.70% – Time to Invest? - investchronicle.com
Celularity Inc (CELU) Stock: A Year of Market Fluctuations - investchronicle.com
Bilibili Inc ADR (BILI) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Captivision Inc Inc. (CAPT) Price Performance: The Role of Supply and Demand - investchronicle.com
Charting the Course: Castellum Inc’s CTM Stock Prospects - investchronicle.com
MBIO Stock: Exploring Mustang Bio Inc’s Growth - investchronicle.com
IBG’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
IBIO’s Market Whiplash: -61.36% YTD Decline, -20.36% Plunge in 30 Days - investchronicle.com
LQR House Inc (YHC) Stock: A Year of Stock Market Dynamics - investchronicle.com
INKT’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Crossmark Global Holdings Inc. Reduces Stock Holdings in ARM Holdings PLC Sponsored ADR (NASDAQ:ARM) - Defense World
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults - The Globe and Mail
FDA Accepts GSK Filing For Expanded Use Of RSV Shot In Younger Adults - Barchart.com
Argentina Lithium & Energy (CVE:LIT) Shares Down 12.5% – What’s Next? - Defense World
Brown Advisory Inc. Increases Holdings in Invesco BulletShares 2026 Corporate Bond ETF (NASDAQ:BSCQ) - Defense World
Callan Capital LLC Raises Stock Holdings in Alphabet Inc. (NASDAQ:GOOGL) - Defense World
Brown Advisory Inc. Boosts Position in Schwab US Large-Cap ETF (NYSEARCA:SCHX) - Defense World
KBR, Inc. (NYSE:KBR) Holdings Trimmed by M&T Bank Corp - Defense World
Invesco RAFI Developed Markets ex-U.S. ETF (NYSEARCA:PXF) Position Increased by Bank of New York Mellon Corp - Defense World
Verisk Analytics, Inc. (NASDAQ:VRSK) Shares Sold by Stratos Wealth Partners LTD. - Defense World
Post Resch Tallon Group Inc. Has $818,000 Stock Position in NVIDIA Corporation (NASDAQ:NVDA) - Defense World
Alphabet Inc. (NASDAQ:GOOGL) Shares Purchased by Interchange Capital Partners LLC - Defense World
Crossmark Global Holdings Inc. Purchases New Stake in Cushman & Wakefield PLC (NYSE:CWK) - Defense World
4,270 Shares in iShares California Muni Bond ETF (NYSEARCA:CMF) Bought by Crossmark Global Holdings Inc. - Defense World
Wall Street Zen Upgrades LCI Industries (NYSE:LCII) to Buy - Defense World
Citigroup Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock - Defense World
Is Your Investment Portfolio Ready for a US-EU Trade Deal? - Morningstar
Amalgamated Bank Sells 311 Shares of Benchmark Electronics, Inc. (NYSE:BHE) - Defense World
Amalgamated Bank Has $429,000 Stock Position in NetScout Systems, Inc. (NASDAQ:NTCT) - Defense World
Amalgamated Bank Trims Stock Position in National Bank Holdings Corporation (NYSE:NBHC) - Defense World
The 10 Best Companies to Invest in Now - Morningstar
GENFIT (NASDAQ:GNFT) Shares Up 0.7% – Time to Buy? - Defense World
글락소스미스클라인 ADR (GSK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
1.44%
자본화:
|
볼륨(24시간):